메뉴 건너뛰기




Volumn 29, Issue 11, 2013, Pages 998-1003

Hepatitis C virus: 25 years-old, the end?;Virus de l'hépatite C: 25 ans, la fin de l'histoire?

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG DERIVATIVE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

EID: 84889676798     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20132911016     Document Type: Review
Times cited : (7)

References (30)
  • 1
    • 62549157097 scopus 로고    scopus 로고
    • HCV-related burden of disease in Europe: A systematic assessment of incidence, prevalence, morbidity, and mortality
    • Muhlberger, N; Schwarzer, R; Lettmeier, B; et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9: 34.
    • (2009) BMC Public Health , vol.9 , pp. 34
    • Muhlberger, N.1    Schwarzer, R.2    Lettmeier, B.3
  • 2
    • 77953123259 scopus 로고    scopus 로고
    • Mortality in patients with chronic and cleared hepatitis C viral infection: A nationwide cohort study
    • Omland, LH; Krarup, H; Jepsen, P; et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010; 53: 36-42.
    • (2010) J Hepatol , vol.53 , pp. 36-42
    • Omland, L.H.1    Krarup, H.2    Jepsen, P.3
  • 3
    • 36549067746 scopus 로고    scopus 로고
    • The changing epidemiology of hepatitis C virus infection in Europe
    • DOI 10.1016/j.jhep.2007.07.033, PII S0168827807005739
    • Esteban, JI; Sauleda, S; Quer, J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-162. (Pubitemid 350191999)
    • (2008) Journal of Hepatology , vol.48 , Issue.1 , pp. 148-162
    • Esteban, J.I.1    Sauleda, S.2    Quer, J.3
  • 4
    • 79960453276 scopus 로고    scopus 로고
    • EASL clinical practice guidelines: Management of chronic hepatitis C virus infection
    • European association for the study of the liver
    • European association for the study of the liver. EASL clinical practice guidelines: management of chronic hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
    • (2011) J Hepatol , vol.55 , pp. 245-264
  • 6
    • 0034221590 scopus 로고    scopus 로고
    • Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa
    • Fontaine, H; Chaix, ML; Lagneau, JL; et al. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa. Lancet 2000; 356: 41. (Pubitemid 30416995)
    • (2000) Lancet , vol.355 , Issue.9223 , pp. 41
    • Fontaine, H.1    Chaix, M.-L.2    Lagneau, J.-L.3    Brechot, C.4    Pol, S.5
  • 7
    • 68249154875 scopus 로고    scopus 로고
    • Peginterferon alfa-2b or alfa-2a with ribavirin for treatement of hepatitis C infection
    • Mchutchison, JG; Lawitz, EJ; Shiffman, ML; et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatement of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
    • (2009) N Engl J Med , vol.361 , pp. 580-593
    • McHutchison, J.G.1    Lawitz, E.J.2    Shiffman, M.L.3
  • 9
    • 51949117672 scopus 로고    scopus 로고
    • Brief communication: The relationship of regression of cirrhosis to outcome in chronic hepatitis C
    • Mallet, V; Gilgenkrantz, H; Serpaggi, J; et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
    • (2008) Ann Intern Med , vol.149 , pp. 399-403
    • Mallet, V.1    Gilgenkrantz, H.2    Serpaggi, J.3
  • 10
    • 84866898184 scopus 로고    scopus 로고
    • Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study
    • Lee, MH; Yang, HI; Lu, SN; et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012; 206: 469-477.
    • (2012) J Infect Dis , vol.206 , pp. 469-477
    • Lee, M.H.1    Yang, H.I.2    Lu, S.N.3
  • 11
    • 84864915019 scopus 로고    scopus 로고
    • Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus
    • Berenguer, J; Rodríguez, E; Miralles, P; et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 55: 728-736.
    • (2012) Clin Infect Dis , vol.55 , pp. 728-736
    • Berenguer, J.1    Rodríguez, E.2    Miralles, P.3
  • 12
    • 34249024924 scopus 로고    scopus 로고
    • Replication of hepatitis C virus
    • DOI 10.1038/nrmicro1645, PII NRMICRO1645
    • Moradpour, D; Penin, F; Rice, CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463. (Pubitemid 46780082)
    • (2007) Nature Reviews Microbiology , vol.5 , Issue.6 , pp. 453-463
    • Moradpour, D.1    Penin, F.2    Rice, C.M.3
  • 13
    • 84855212109 scopus 로고    scopus 로고
    • New targets for antiviral therapy of chronic hepatitis C
    • Buhler, S; Bartenschlager, R. New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012; 32: 19-16.
    • (2012) Liver Int , vol.32 , pp. 19-16
    • Buhler, S.1    Bartenschlager, R.2
  • 14
    • 82955236108 scopus 로고    scopus 로고
    • Anti-HCV drugs in the pipeline
    • Yang, PL; Gao, M; Lin, K; et al. Anti-HCV drugs in the pipeline. Curr Opin Virol 2011; 1: 607-616.
    • (2011) Curr Opin Virol , vol.1 , pp. 607-616
    • Yang, P.L.1    Gao, M.2    Lin, K.3
  • 15
    • 65449171953 scopus 로고    scopus 로고
    • Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    • Hezode, C; Forestier, N; Dusheiko, G; et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
    • (2009) N Engl J Med , vol.360 , pp. 1839-1850
    • Hezode, C.1    Forestier, N.2    Dusheiko, G.3
  • 16
    • 77956268467 scopus 로고    scopus 로고
    • Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentric phase 2 trial
    • Kwo, PY; Lawitz, EJ; McCone, J; et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentric phase 2 trial. Lancet 2011; 376: 705-716.
    • (2011) Lancet , vol.376 , pp. 705-716
    • Kwo, P.Y.1    Lawitz, E.J.2    McCone, J.3
  • 17
    • 77950817619 scopus 로고    scopus 로고
    • Telaprevir for previously treated chronic HCV infection
    • McHutchison, JG; Manns, MP; Muir, AJ; et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
    • (2010) N Engl J Med , vol.362 , pp. 1292-1303
    • McHutchison, J.G.1    Manns, M.P.2    Muir, A.J.3
  • 18
    • 79959381354 scopus 로고    scopus 로고
    • Telaprevir for retreatment of HCV infection
    • Zeuzem, S; Andreone, P; Pol, S; et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
    • (2011) N Engl J Med , vol.364 , pp. 2417-2428
    • Zeuzem, S.1    Andreone, P.2    Pol, S.3
  • 19
    • 79953176289 scopus 로고    scopus 로고
    • Boceprevir for previously treated chronic HCV genotype 1 infection
    • Bacon, BR; Gordon, SC; Lawitz, E; et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
    • (2011) N Engl J Med , vol.364 , pp. 1207-1217
    • Bacon, B.R.1    Gordon, S.C.2    Lawitz, E.3
  • 20
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • Jacobson, IM; McHutchison, JG; Dusheiko, G; et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
    • (2011) N Engl J Med , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchison, J.G.2    Dusheiko, G.3
  • 21
    • 84855924980 scopus 로고    scopus 로고
    • Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals
    • Cacoub, P; Bourlière, M; Lübbe, J; et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012; 56: 455-463.
    • (2012) J Hepatol , vol.56 , pp. 455-463
    • Cacoub, P.1    Bourlière, M.2    Lübbe, J.3
  • 23
    • 84878976866 scopus 로고    scopus 로고
    • Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype 1, infection (ATOMIC): An open-label, randomised, multicentre, phase 2 trial
    • Kowdley, KV; Lawitz, E; Crespo, I; et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype 1, infection (ATOMIC): an open-label, randomised, multicentre, phase 2 trial. Lancet 2013; 381: 2100-2107.
    • (2013) Lancet , vol.381 , pp. 2100-2107
    • Kowdley, K.V.1    Lawitz, E.2    Crespo, I.3
  • 24
    • 78049527728 scopus 로고    scopus 로고
    • Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and Danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, double-blind, placebo-controlled, dose-escalation trial
    • Gane, EJ; Roberts, SK; Stedman, CA; et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and Danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475.
    • (2010) Lancet , vol.376 , pp. 1467-1475
    • Gane, E.J.1    Roberts, S.K.2    Stedman, C.A.3
  • 25
    • 84865285928 scopus 로고    scopus 로고
    • Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: A randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
    • Pol, S; Ghalib, RH; Rustgi, VK; et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12: 671-677.
    • (2012) Lancet Infect Dis , vol.12 , pp. 671-677
    • Pol, S.1    Ghalib, R.H.2    Rustgi, V.K.3
  • 26
    • 81855228070 scopus 로고    scopus 로고
    • Efficacy of the protease inhibitor BI 201335, the polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C
    • Zeuzem, S; Asselah, T; Angus, PW; et al. Efficacy of the protease inhibitor BI 201335, the polymerase inhibitor BI 207127 and ribavirin in patients with chronic hepatitis C. Gastroenterology 2011; 141: 2047-2055.
    • (2011) Gastroenterology , vol.141 , pp. 2047-2055
    • Zeuzem, S.1    Asselah, T.2    Angus, P.W.3
  • 27
    • 84874105854 scopus 로고    scopus 로고
    • Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202)
    • Lenz, O; Vijgen, L; Berke, JM; et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 2013; 58: 445-451.
    • (2013) J Hepatol , vol.58 , pp. 445-451
    • Lenz, O.1    Vijgen, L.2    Berke, J.M.3
  • 28
    • 84856159009 scopus 로고    scopus 로고
    • Preliminary study of two antiviral agents for hepatitis C genotype 1
    • Lok, AS; Gardiner, DF; Lawitz, E; et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224.
    • (2012) N Engl J Med , vol.366 , pp. 216-224
    • Lok, A.S.1    Gardiner, D.F.2    Lawitz, E.3
  • 29
    • 84871814966 scopus 로고    scopus 로고
    • Nucleotide polymerase inhibitor Sofosbuvir plus ribavirin for hepatitis C
    • Gane, EJ; Stedman, CA; Hyland, RH; et al. Nucleotide polymerase inhibitor Sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
    • (2013) N Engl J Med , vol.368 , pp. 34-44
    • Gane, E.J.1    Stedman, C.A.2    Hyland, R.H.3
  • 30
    • 84889666210 scopus 로고    scopus 로고
    • Exploratory study of oral combination antiviral therapy for hepatitis C
    • Poordard, F; Lawitz, E; Kowdley, KV; et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 56: S560.
    • (2013) N Engl J Med , vol.56
    • Poordard, F.1    Lawitz, E.2    Kowdley, K.V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.